Piper Sandler lowered the firm’s price target on Inspire Medical (INSP) to $150 from $233 and keeps an Overweight rating on the shares following quarterly results. While Q2 was better-than-feared, the focus of the EPS call was regarding the company’s revised FY2025 guidance, which was lowered sharply to account for several headwinds – most of which are related to the gen 5 rollout. While the firm had suspected that “we could see a downward revision, we were disappointed by the magnitude of the cut to both the top and bottom-line guide,” which has shares indicated down 20%-plus after hours.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Morning Movers: Palantir and Leidos gain after quarterly reports
- Inspire Medical price target lowered to $150 from $270 at Lake Street
- Inspire Medical price target lowered to $140 from $175 at Stifel
- Inspire Medical price target lowered to $230 from $270 at UBS
- Inspire Medical downgraded to Hold from Buy at Truist